Bayer is looking for Preclinical Imaging Scientist

  • Denne stillingen er besatt

bayer Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.

Preclinical Imaging Scientist

The Imaging & Radiobiology group within Bayer AS is looking for a highly motivated Imaging scientist to join the Targeted Radiopharmaceutical (TRP) department. The Imaging scientist will play a key role in performing preclinical imaging studies using PET /SPECT/µCT, MRI, Optical imaging technologies, biomedical image data processing and analysis in addition to pharmacokinetic (PK) and pharmacodynamic (PD) studies of our targeted alpha therapies.

This laboratory-based position offers an exciting opportunity to be part of a dynamic team developing new radiotherapies for the treatment of cancer.

Key Responsibilities:

  • Ensure a safe and compliant preclinical laboratory environment.
  • Responsible for applying expertise and experimental skills to execute preclinical imaging experiments in addition to PK/PD studies in a time sensitive manner, including experimental planning and preparation, protocol design/validation, operating various imaging systems and other instruments, animal handling, imaging data acquisition and experimental documentation.
  • Perform quantitative analysis of imaging data using state-of-the-art software tools, and prepare documentation and data analysis summary, such as study reports and presentations.
  • Work with scientists and other departments, develop and maintain a culture of teamwork and collaboration, in a multidisciplinary environment.



  • Ph.D. in Biomedical Engineering, Biophysics/Biochemistry, Biotechnology, Radiochemistry, Biology or a related field with at least 3 years of research experience in life sciences. Master’s degree with a minimum of 5 years’ relevant experience and strong skills will also be considered.
  • Previous experience/expertise in small animal imaging modalities MRI, PET, SPECT, optical and/or µCT as well as biomedical image processing and data analysis is desirable
  • In vivo small animal handling skills such as surgical procedures, IV and IP injections, familiarity with animal welfare protocols/guidelines (FELASA C certified) for the conduct of in vivo studies, is a requirement.
  • Experience with handling radioactivity for preclinical experimentation is highly preferred but not essential.
  • Excellent written and verbal communication skills. Proven abilities to work in a team environment with high motivation and strong work ethics.


We offer:

We can offer positive work environment at our nice offices at Lysaker. In addition to competitive benefits we can also offer good development opportunities.


Contact information:

The recruitment process is carried out in collaboration with the external recruiter consulting company Borka Consulting AS.
If you would like to find out more about this position before submitting your application, please do not hesitate to contact Cecilie Fraas Borka, phone +47 928 55 352 or email to


Application Process:

To be considered for this great opportunity, please use the link in this portal:
to apply and upload your CV and motivational letter as soon as possible, no later than March 3rd 2022.
Candidates will be reviewed on a continuous basis.


Del dette: